Moheiddin Alghobary
Research Subjects
Moheiddin Alghobary has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Frank Comhaire
Emeritus Professor of Andrology Ghent University Hospital Ghent Belgium
2 shared publications - Abheesh Varma Hegde
Father Muller Medical College Hospital
1 shared publication Adel Zalata
Medical Biochemistry Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication- Adel Zalata
Department of Biochemistry & Molecular Biology Faculty of Medicine Mansoura University Mansoura Egypt
1 shared publication - Ahmad Motawi
Department of Andrology, Sexology & STIs, Faculty of Medicine, Cairo University, Cairo, Egypt
1 shared publication - Ahmed Abd Elmoaty Khalifa
Global Andrology Forum, Global Andrology Foundation, Moreland Hills, OH, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Global Andrology Forum Clinical Guidelines on Antioxidant Use in the Treatment of Male Infertility
Agarwal A, et al. World J Mens Health. 2026 Jan;44:e3. https://doi.org/10.5534/wjmh.250290
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Top Cited PapersOpen AccessGlobal Andrology Forum Clinical Guidelines on Antioxidant Use in the Treatment of Male Infertility
Agarwal A, et al. World J Mens Health. 2026 Jan;44:e3. https://doi.org/10.5534/wjmh.250290
- Open Access
- 22 May 2020
- Published by Hindawi Limited in Andrologia
- Vol. 52 (7) , e13659
The possible role of NF‐κB1 Rs28362491 polymorphism in male fertility of Egyptian population
Male reproductive impairment is responsible for at least 50% of cases of couple infertility. Nuclear factor‐kappa B (NF‐κB) has been functionally linked to germ cell apoptosis, which may affect human fertility. The aim of this study was to determine the association between the rs28362491 SNP of the NF‐κB1 gene and infertility in Egyptian men. In this case–control study, semen and blood samples of 247 infertile men, constituting the case group, and of 113 fertile healthy men as the control group were analysed. All study participants were genotyped for polymorphism of the NF‐κB1 gene (rs28362491) by the polymerase chain reaction—restriction fragment length polymorphism (PCR‐RFLP) technique. Heterozygous I/D genotype of the NF‐κB1 rs28362491 polymorphism was associated with a significantly lower risk of poor semen quality, including asthenozoospermia, astheno–teratozoospermia, and oligo–astheno–teratozoospermia, when compared to I/I genotype (odds ratio = 0.25, 0.26, 0.18, p < .0005, <.0005, <.0005) respectively. Overall, the presence of the D allele was associated with a significantly decreased risk of poor sperm quality as compared to the I allele (odds ratio = 0.56, 0.64, 0.49, p = .050, .038, .001). In conclusion, these results suggest that heterozygosity of the NF‐κB1 gene may play a protecting role against male infertility in Egyptians.
- 22 May 2020
- Published by Hindawi Limited in Andrologia
- Vol. 52 (7) , e13659
Open AccessThe possible role of NF‐κB1 Rs28362491 polymorphism in male fertility of Egyptian population
Male reproductive impairment is responsible for at least 50% of cases of couple infertility. Nuclear factor‐kappa B (NF‐κB) has been functionally linked to germ cell apoptosis, which may affect human fertility. The aim of this study was to determine the association between the rs28362491 SNP of the NF‐κB1 gene and infertility in Egyptian men. In this case–control study, semen and blood samples of 247 infertile men, constituting the case group, and of 113 fertile healthy men as the control group were analysed. All study participants were genotyped for polymorphism of the NF‐κB1 gene (rs28362491) by the polymerase chain reaction—restriction fragment length polymorphism (PCR‐RFLP) technique. Heterozygous I/D genotype of the NF‐κB1 rs28362491 polymorphism was associated with a significantly lower risk of poor semen quality, including asthenozoospermia, astheno–teratozoospermia, and oligo–astheno–teratozoospermia, when compared to I/I genotype (odds ratio = 0.25, 0.26, 0.18, p < .0005, <.0005, <.0005) respectively. Overall, the presence of the D allele was associated with a significantly decreased risk of poor sperm quality as compared to the I allele (odds ratio = 0.56, 0.64, 0.49, p = .050, .038, .001). In conclusion, these results suggest that heterozygosity of the NF‐κB1 gene may play a protecting role against male infertility in Egyptians.
- 9 March 2020
- Published by Hindawi Limited in Andrologia
- Vol. 52 (5) , e13558
Oral dapoxetine versus topical lidocaine as on‐demand treatment for lifelong premature ejaculation: A randomised controlled trial
This trial aimed to assess the efficacy of on‐demand oral dapoxetine versus topical lidocaine treatments for lifelong PE. Cases with lifelong PE were randomised to start treatment by oral dapoxetine 60 mg or topical lidocaine 10% spray. The intravaginal ejaculatory latency time (ILET), validated Arabic Index for PE (AIPE), Sexual Health Inventory for Men (SHIM) and frequency of intercourse/week were recorded at the baseline and after 12 weeks treatment period of the first medication before two weeks washout period and then crossing over to the other one for another 12 weeks. Results showed that both medications significantly increased both IELT and AIPE scores compared with the baseline being significantly better with topical lidocaine (63.44 s, 179.4 s versus 21.87 s, p < .05). Significant decrease of SHIM score was recorded with lidocaine but not with dapoxetine. Global Efficacy Question for the patient's assessment of the effectiveness of drugs showed that lidocaine was described as being effective by 43 cases and ineffective by 12 cases, oral dapoxetine was described as being effective by 16 cases and ineffective by 39 cases. From these accumulated data, it is concluded that topical lidocaine is more effective on‐demand therapy for lifelong PE compared with oral dapoxetine.
- 9 March 2020
- Published by Hindawi Limited in Andrologia
- Vol. 52 (5) , e13558
Oral dapoxetine versus topical lidocaine as on‐demand treatment for lifelong premature ejaculation: A randomised controlled trial
This trial aimed to assess the efficacy of on‐demand oral dapoxetine versus topical lidocaine treatments for lifelong PE. Cases with lifelong PE were randomised to start treatment by oral dapoxetine 60 mg or topical lidocaine 10% spray. The intravaginal ejaculatory latency time (ILET), validated Arabic Index for PE (AIPE), Sexual Health Inventory for Men (SHIM) and frequency of intercourse/week were recorded at the baseline and after 12 weeks treatment period of the first medication before two weeks washout period and then crossing over to the other one for another 12 weeks. Results showed that both medications significantly increased both IELT and AIPE scores compared with the baseline being significantly better with topical lidocaine (63.44 s, 179.4 s versus 21.87 s, p < .05). Significant decrease of SHIM score was recorded with lidocaine but not with dapoxetine. Global Efficacy Question for the patient's assessment of the effectiveness of drugs showed that lidocaine was described as being effective by 43 cases and ineffective by 12 cases, oral dapoxetine was described as being effective by 16 cases and ineffective by 39 cases. From these accumulated data, it is concluded that topical lidocaine is more effective on‐demand therapy for lifelong PE compared with oral dapoxetine.
- 16 February 2020
- Published by Wiley in Andrologia
- Vol. 52 (4) , e13532
Evaluation of cannabinoid receptors Type 1 and Type 2 mRNA expression in mature versus immature spermatozoa from fertile and infertile males
The expression of the main cannabinoid receptors (CBR1 and CBR2) was investigated to evaluate the possible association with the sperm maturation from fertile and infertile individuals. One hundred subjects were classified into fertile (n = 50) and infertile groups (n = 50). Fresh semen samples were collected. Computer‐assisted semen analysis and acrosin activity test were done. RNA was extracted from mature and immature sperm pellets. Reverse transcriptase reaction and real‐time PCR were done to assess the levels of both CBR1 and CBR2 genes expression in all samples. Mature spermatozoa from both groups showed significantly higher levels of both CBR1 and CBR2 compared with the immature spermatozoa (p < .05). This increment was significantly more important in the fertile group (p < .05). In mature spermatozoa, CBR1 expression was significantly related to variation in sperm morphology, and CBR2 was significantly related to both sperm morphology and linearity index. In conclusion, CBR1 and CBR2 mRNA expression may closely direct the sperm maturation at different steps of the reproductive process.
- 16 February 2020
- Published by Wiley in Andrologia
- Vol. 52 (4) , e13532
Evaluation of cannabinoid receptors Type 1 and Type 2 mRNA expression in mature versus immature spermatozoa from fertile and infertile males
The expression of the main cannabinoid receptors (CBR1 and CBR2) was investigated to evaluate the possible association with the sperm maturation from fertile and infertile individuals. One hundred subjects were classified into fertile (n = 50) and infertile groups (n = 50). Fresh semen samples were collected. Computer‐assisted semen analysis and acrosin activity test were done. RNA was extracted from mature and immature sperm pellets. Reverse transcriptase reaction and real‐time PCR were done to assess the levels of both CBR1 and CBR2 genes expression in all samples. Mature spermatozoa from both groups showed significantly higher levels of both CBR1 and CBR2 compared with the immature spermatozoa (p < .05). This increment was significantly more important in the fertile group (p < .05). In mature spermatozoa, CBR1 expression was significantly related to variation in sperm morphology, and CBR2 was significantly related to both sperm morphology and linearity index. In conclusion, CBR1 and CBR2 mRNA expression may closely direct the sperm maturation at different steps of the reproductive process.
- 1 August 2010
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 7 (8) , 2860-2867
Evaluation of Tramadol on Demand Vs. Daily Paroxetine as a Long-Term Treatment of Lifelong Premature Ejaculation
Introduction: Premature ejaculation (PE) is the most common male sexual dysfunction with many lines of treatment that show conflicting results. Paroxetine and tramadol were both reported to be effective in treatment of PE. Aim: To investigate the effectiveness of long-term daily paroxetine vs. on-demand tramadol HCl in treatment of PE. Main Outcome Measures: Intravaginal ejaculatory latency time (IELT) and Arabic Index of PE (AIPE) were used to assess the efficacy of investigated drugs. Methods: Thirty-five cases with lifelong PE were enrolled in this study. Baseline recording of IELT using a stop watch and AIPE was done. Patients were randomized to take tramadol HCl on-demand or daily paroxetine. Reassessment was done after 6 and 12 weeks. A wash-out period for 2 weeks was given before cross-over to the other medication. Assessment of the effect of the second medication after 6 and 12 weeks was done. Results: Tramadol and paroxetine increased IELT significantly after 6 weeks by seven- and 11-folds, respectively, compared with baseline. After 12 weeks, a decline of IELT to fivefolds was recorded with tramadol whereas further increase of IELT to 22-folds was recorded with paroxetine compared with baseline (P <0.05). Tramadol improved AIPE score significantly after 6 weeks but not after 12 weeks vs. baseline, whereas paroxetine increased the AIPE score after 6 and 12 weeks vs. baseline (P <0.05). Conclusions: Daily paroxetine is more effective than on-demand tramadol for treatment of lifelong PE. Tramadol is not recommended as a long-term treatment of lifelong PE.
- 1 August 2010
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 7 (8) , 2860-2867
Evaluation of Tramadol on Demand Vs. Daily Paroxetine as a Long-Term Treatment of Lifelong Premature Ejaculation
Introduction: Premature ejaculation (PE) is the most common male sexual dysfunction with many lines of treatment that show conflicting results. Paroxetine and tramadol were both reported to be effective in treatment of PE. Aim: To investigate the effectiveness of long-term daily paroxetine vs. on-demand tramadol HCl in treatment of PE. Main Outcome Measures: Intravaginal ejaculatory latency time (IELT) and Arabic Index of PE (AIPE) were used to assess the efficacy of investigated drugs. Methods: Thirty-five cases with lifelong PE were enrolled in this study. Baseline recording of IELT using a stop watch and AIPE was done. Patients were randomized to take tramadol HCl on-demand or daily paroxetine. Reassessment was done after 6 and 12 weeks. A wash-out period for 2 weeks was given before cross-over to the other medication. Assessment of the effect of the second medication after 6 and 12 weeks was done. Results: Tramadol and paroxetine increased IELT significantly after 6 weeks by seven- and 11-folds, respectively, compared with baseline. After 12 weeks, a decline of IELT to fivefolds was recorded with tramadol whereas further increase of IELT to 22-folds was recorded with paroxetine compared with baseline (P <0.05). Tramadol improved AIPE score significantly after 6 weeks but not after 12 weeks vs. baseline, whereas paroxetine increased the AIPE score after 6 and 12 weeks vs. baseline (P <0.05). Conclusions: Daily paroxetine is more effective than on-demand tramadol for treatment of lifelong PE. Tramadol is not recommended as a long-term treatment of lifelong PE.